Cell Genesys Shares Rise After Mention in Column

The shares of Cell Genesys Inc. jumped for a second straight day after the company's experimental cancer vaccines were mentioned in the magazine Business Week.

The shares rose by 26 cents, or 7.9 percent, to $3.57 at 4 p.m. New York time in Nasdaq stock market composite trading after rising 7.8 percent yesterday. The shares are down 40 percent from a year earlier.

The South San Francisco, California, company has clinical trials under way for vaccines against prostate and pancreatic cancer. The company is likely to present encouraging interim data in June from clinical research, Business Week reported yesterday, citing analyst Pamela Bassett at Cantor Fitzgerald.

To contact the reporter on this story: Robert Greene in Washington at rgreene2@bloomberg.net.

To contact the editor responsible for this story: Robert Simison at rsimison@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.